Nutra Pharma Corp (NPHC)

[Goofy R]

$80 TOTAL VOLUME!!BWHAHAHAHAA!!YUP...FILPPERS-MAKING-BIG-MONEY!!BWHAHAHAHHAAAAA!!!!



$64 MILLION DEFICIT!!!

MASSIVE LOSSES!!! SEE BELOW!!

MASSIVE DEBT!! SEE BELOW!!

ZERO REVENUES!!! SEE BELOW!!!

SEC FRAUD AND ILLEGAL STOCK MANIPULATION LAWSUIT!!

https://www.sec.gov/litigation/complaints/2018/comp24295.pdf


RIK'S CRIMINAL ASSOCIATES (WITH NPHC):
Phil Piccolo:

http://worldwidescam.com/sumphil.htm


SEAN PETER McMANUS:

https://structuredsettlements.typepad.com/structured_settlements_4r/2019/01/patriot-settlement-resources-mcmanus-sued-by-finra-for-selling-snake-oil-without-a-license.html

Waiora Lawsuit against Rik (Fake Ingredients/Fraud):


https://www.law360.com/articles/922469/health-co-barred-from-selling-supplement-in-ip-row

Tommy Edward Crutchfield (Snake Guy in the video):

https://www.justice.gov/archive/opa/pr/1999/April/140enr.htm

Dr. Keith Gordon, DMV (Pet Pain Away Spokesperson):

https://www.mycentraljersey.com/story/news/local/middlesex-county/2015/12/28/fancy-pups-avenel-closed-owner-arrested/77981976/

COMPLAINT FOR PATENT INFRINGEMENT, BREACH OF LICENSE AGREEMENT, FRAUD AND RELATED CLAIMS (JURY DEMAND ENDORSED HEREON):

https://insight.rpxcorp.com/litigation_documents/2326309

Excerpt:

Rik’s FRAUD!!!:

22. Although Deitsch and NDA arranged to begin manufacture and sale of Product, they refused to inform Plaintiff, on later inquiries, of any manufacturing details, including the identity of the manufacturer. Case: 5:07-cv-00785-JG Doc #: 1 Filed: 03/16/07 8 of 16. PageID #: 62
-9-23.
Shortly after entering into the Agreement, NDA claimed to encounter problems with its marketing efforts in Germany. In a June 30, 2004, e-mail from his “nutrapharma” e-mail address, Deitsch informed Plaintiff of problems with “the German group” and the manufacturing of the Product.
Plaintiff now believes that no “German Division of MRI Labs” was available to NDA and that Deitsch misrepresented his German marketing infrastructure to induce Plaintiff to enter into the Agreement.



NUTRA PHARMA CORP.
Consolidated Statements of Operations


For the Years Ended
December 31,
2017 2016
Net sales $ 120,979 168,356
Cost of sales 26,903 38,965
Impairment of inventory - 184,039
Gross profit (54,648)

Operating expenses:
Selling, general and administrative - including stock based compensation of $73,576 and $390,608 for the years ended December 31, 2017 and 2016, respectively 1,476,016 1,988,868
Total operating expenses 1,476,016 1,988,868
Loss from operations (2,043,516)

Other (income) expenses
Rental income - 19,381
Interest expense (358,651) (293,785)
Change in fair value of derivatives (2,273,968) (1,258,649)
Gain (Loss) on settlement of indebtedness, net (14,189) 128,956
Other expenses (2,646,808) (1,404,097)
Net loss before income taxes (4,028,748) (3,447,613)
Provision for income taxes - -
Net loss $(4,028,748) (3,447,613)